Cancer studies often lack necessary rigor to answer key questions
DURHAM, N.C. – Fueled in part by an inclination to speed new treatments to patients, research studies for cancer therapies tend to be smaller and less robust than for other diseases.
This raises some questions about how cancer therapies will work in practice, according to researchers at Duke Medicine, who published an analysis of nearly 9,000 oncology clinical research studies online April 29, 2013, in the journal JAMA Internal Medicine. The studies they looked at were registered on the ClinicalTrials.gov website from 2007-10.
The analysis is part of the Clinical Trials ...